Entrada Therapeutics (US:TRDA) — Company Overview, News & Financial Data

Entrada Therapeutics logo
TRDAEntrada Therapeutics
Trade TRDA now
Entrada Therapeutics primary media

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ:TRDA) is a biotechnology firm focused on the development of innovative therapies. The company specializes in creating drugs designed to engage intracellular targets, aiming to treat a broad range of diseases, including neuromuscular conditions and other serious ailments. Entrada Therapeutics is leveraging its proprietary platform to advance a portfolio of oligonucleotide and peptide therapeutics aimed at addressing unmet medical needs. With a commitment to science and patient care driving its operations, the firm is dedicated to pushing the boundaries of medicine to improve the lives of patients worldwide.

What is TRDA known for?

Snapshot

Public US
Ownership
2016
Year founded
169
Employees
Boston, United States
Head office
Loading Map...

Operations

All Locations
Boston, US

Products and/or services of Entrada Therapeutics

  • Developing an intracellular biologics delivery platform aimed at transforming the treatment of devastating diseases.
  • Focusing on a Duchenne Muscular Dystrophy (DMD) program, leveraging their platform to address this genetic disorder.
  • Advancing programs targeting Myotonic Dystrophy Type 1, utilizing novel therapeutics for this neuromuscular disease.
  • Creating a broad pipeline of endosomal escape vehicle (EEV™)-fueled therapies for various diseases.
  • Offering research and development services to create custom intracellular delivery solutions for biopharmaceutical companies.
  • Exploring potential treatments for other rare diseases through their proprietary technology platform.

Entrada Therapeutics executive team

  • Mr. Dipal DoshiCEO & Director
  • Mr. Nathan J. DowdenPresident & COO
  • Dr. Natarajan Sethuraman Ph.D.President of Research & Development
  • Mr. Kory James Wentworth CPACFO & Treasurer
  • Dr. Jared Cohen J.D., Ph.D.General Counsel
  • Ms. Karla MacDonaldChief Corporate Affairs Officer
  • Mr. Kevin Healy Ph.D.Senior Vice President of Regulatory Affairs
  • Sandeep BasnetHead of Information Technology

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.